An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 103 participants.

Also called NCT02962648

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 103 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02962648
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02962648. Allocation not applicable; no masking; primary purpose treatment. Start 2017-01-09 (actual); primary completion 2018-06-12 (actual). Results posted on 2020-03-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Extension Trial to Assess the Safety of Re-dosing of Iron Isomaltoside/Ferric Derisomaltose (Monofer®/Monoferric®)
Acronym
FERWON-EXT
Condition
Iron Deficiency Anemia
Condition
Iron Deficiency Anaemia
Intervention (Drug)
Iron isomaltoside/ferric derisomaltose
Lead sponsor
Pharmacosmos A/S (class: industry)

Record details

Record id
cardio:ct-nct02962648
Content hash
59a6d0f2640091a29d64d9ccf7e5e9f7d6660f3c216329fb45bd1140112d1891